Company Quick10K Filing
Quantrx Biomedical
10-Q 2020-03-31 Filed 2020-05-20
10-K 2019-12-31 Filed 2020-04-14
10-Q 2019-09-30 Filed 2019-11-19
10-Q 2019-06-30 Filed 2019-08-15
10-Q 2019-03-31 Filed 2019-05-20
10-K 2018-12-31 Filed 2019-04-16
10-Q 2018-09-30 Filed 2018-11-19
10-Q 2018-06-30 Filed 2018-08-20
10-Q 2018-03-31 Filed 2018-05-21
10-K 2017-12-31 Filed 2018-04-17
10-Q 2017-09-30 Filed 2017-11-20
10-Q 2017-06-30 Filed 2017-08-21
10-Q 2017-03-31 Filed 2017-05-22
10-K 2016-12-31 Filed 2017-04-17
10-Q 2016-09-30 Filed 2016-12-02
10-Q 2016-06-30 Filed 2016-08-17
10-Q 2016-03-31 Filed 2016-05-20
10-K 2015-12-31 Filed 2016-04-13
10-Q 2015-09-30 Filed 2015-11-16
10-Q 2015-06-30 Filed 2015-08-17
10-Q 2015-03-31 Filed 2015-07-22
10-K 2014-12-31 Filed 2015-04-15
10-Q 2014-09-30 Filed 2014-11-18
10-Q 2014-06-28 Filed 2014-08-19
10-Q 2014-03-31 Filed 2014-05-20
10-K 2013-12-31 Filed 2014-04-14
10-Q 2013-09-30 Filed 2013-11-19
10-Q 2013-06-30 Filed 2013-08-14
10-Q 2013-03-31 Filed 2013-05-20
10-K 2012-12-31 Filed 2013-04-15
10-Q 2012-06-30 Filed 2012-08-20
10-Q 2012-03-31 Filed 2012-05-21
10-K 2011-12-31 Filed 2012-04-17
10-Q 2011-09-30 Filed 2011-11-18
10-Q 2011-06-30 Filed 2011-08-16
10-Q 2011-03-31 Filed 2011-05-20
10-K 2010-12-31 Filed 2011-04-14
10-Q 2010-09-30 Filed 2010-11-19
10-Q 2010-06-30 Filed 2010-08-06
10-Q 2010-03-31 Filed 2010-05-14
10-K 2009-12-31 Filed 2010-03-31

Quantrx Biomedical Financials

QTXB Metrics, Comps, Filings

Quarterly | Annual

Business

QuantRx Biomedical Corporation was incorporated on December 5, 1986, in the State of Nevada. The Company’s principal business office is located at 10190 SW 90th Avenue, Tualatin, Oregon 97123.

We have developed and intend to commercialize our patented miniform pads (“PADs”) and PAD based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses and other medical needs. We are also developing and intend to commercialize genomic diagnostics for the laboratory market, based on our lateral flow patents. Our platforms include: inSync®, UniqueTM, and OEM branded over-the-counter and laboratory testing products based on our core intellectual property related to our PAD technology.

The continuation of our operations remains contingent upon the receipt of additional financing required to execute our business and operating plan, which is currently focused on the commercialization of our PAD technology either directly or through a joint venture or other relationship intended to increase shareholder value. In the interim, we have nominal operations, focused principally on maintaining our intellectual property portfolio and maintaining compliance with the public company reporting requirements. In order to continue as a going concern, we will need to raise capital, which may include through the issuance of debt and/or equity securities. No assurances can be given that we will be able to obtain additional financing under terms favorable to us, if at all, or otherwise successfully develop a business and operating plan or enter into an alternative relationship to commercialize our PAD technology.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Enertopia (ENRT) 2,549 -5.7 -696% 64 464 0 0 -444 -443 2,535
AbTech (ABHD) 2,524 10% -0.8 -600% 695 14,816 493 51 -4,171 -3,190 2,501
Plastic2Oil (PTOI) 2,495 -3.1 -264% 732 16,922 0 0 -1,932 -855 2,636
US Neurosurgical Holdings (USNU) 2,493 0% 2.6 5% 5,353 2,100 2,324 0 242 420 1,101
YBCC (YBAO) 2,474 25% 36.4 2% 3,851 3,698 1,880 461 65 67 2,436
DDR (DDR) 2,461 0% -0.1 -6% 4,620,092 2,645,101 363,154 0 -283,260 153,686 -10,812
ZZLL Information Technology (ZZLL) 2,433 52% -121.9 -6% 329 1,112 42 21 -20 -20 2,424
Morgan Group Holding (MGHL) 2,430 -35.6 -74% 89 18 0 0 -66 -66 2,350
Amplitech (AMPG) 2,417 51% 128.7 -0% 3,756 2,733 2,018 1,035 -11 25 3,211
CDTI Advanced Materials (CDTI) 2,402 31% 0.2 -66% 7,763 4,765 14,253 4,426 -5,095 -3,933 -852
Alpine 4 Technologies (ALPP) 2,373 25% 2.8 -4% 26,273 37,478 20,690 5,148 -1,162 2,666 7,436
Quantrx Biomedical (QTXB) 2,361 -13.3 -81% 384 2,200 0 0 -309 -166 2,206
Evolutionary Genomics (FNAM) 2,353 0% -4.2 -12% 4,432 975 116 0 -538 -508 2,135
Mount Tam Biotechnologies (MNTM) 2,228 -1.8 -6,794% 20 2,877 0 0 -1,333 -1,248 2,219
Electronic Systems Technology (ELST) 2,228 54% -46.8 -2% 1,982 93 1,141 613 -49 -43 2,028
BioSolar (BSRC) 2,213 2.1 1,165% 145 14,186 0 0 1,685 2,403 4,975
Innerscope Hearing Technologies (INND) 2,206 57% -0.7 -118% 4,220 8,205 657 372 -4,980 -4,663 3,150
Remsleep Holdings (RMSL) 2,194 -0.8 -1,529% 197 1,096 0 0 -3,016 -2,978 2,343
iSIGN Solutions (ISGN) 2,189 0% -2.8 -549% 148 5,210 639 0 -812 -762 2,152
OLB Group (OLBG) 2,187 0% -11,960.1 -11% 11,509 14,314 7,650 0 -1,282 -1 11,661

Balance Sheet ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-282014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash1231811191052141216625421918921484613647135339460403401401322282201155
Accounts Receivable2444262310100000000
Inventory333333322222100
PP&E443935353127444433322221111000000000
Assets5876245865745706104744734384293984673725514914374513963593222792222132372251901,3911,3221,2011,111582531440384
Accounts Payable14418722324326532437537835837628530637840746247446841912212314315316115816717116815714915249585851
Long-Term Debt444444444444444444444444444444414141391,6391,6931,580361,67338390
Liabilities3144264515526687878548949199711,0881,3001,3101,5411,7051,7511,7521,7731,7911,8271,8921,8001,8912,0082,0872,1112,1402,1762,2182,1052,0882,1502,1562,200
Stockholders' Equity27319813522-98-177-380-420-480-542-690-834-938-990-1,215-1,315-1,302-1,377-1,432-1,505-1,614-1,578-1,678-1,771-1,863-1,921-750-855-1,017-993-1,506-1,626-1,716-1,816
Income Statement ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-282014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue2445362311111110000000000
Cost of Revenue
Gross Profit
R&D1315-707144122056163014130000000
SG&A371652195412471759142740511317952253601821132222271717285914231716
Tax000000000000000000000000000000000
Net Income-139-286-189-218-163-148-4123-62-157-184-260-158-225-213-54-110-91-73-108-116-100-93-68-661,120-105-14324-112-97-100
Cash Flow ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-282014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-35-69-46-95-17-24-42-50-31-27-50-84-93-65-65-25-114-22-25-31-11-27-39-26-25-60-57-92-20-40-81-46
Cash Investing00-50000203030303030300-5000000000497000000
Cash Financing5545459515372700136025003635-20-11520742400-61000